Kamada (KMDA) Says FDA Issued Letter Stating that it Continues to Have Concerns and Questions About Safety and Efficacy of Inhaled AAT
Tweet Send to a Friend
Kamada (NASDAQ: KMDA) disclosed in an SEC filing:
As previously disclosed, on July 18, 2017, Kamada Ltd. (the “Company”) submitted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
As previously disclosed, on July 18, 2017, Kamada Ltd. (the “Company”) submitted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
